Legal & General Group Plc Sells 90,358 Shares of Eli Lilly and Company $LLY

Posted by on May 25th, 2026

Legal & General Group Plc lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.7% during the 4th quarter, Holdings Channel reports. The firm owned 5,293,641 shares of the company’s stock after selling 90,358 shares during the period. Eli Lilly and Company comprises about 1.3% of Legal & General Group Plc’s portfolio, making the stock its 11th biggest holding. Legal & General Group Plc’s holdings in Eli Lilly and Company were worth $5,688,970,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Narus Financial Partners LLC raised its stake in Eli Lilly and Company by 23.3% during the 4th quarter. Narus Financial Partners LLC now owns 492 shares of the company’s stock valued at $529,000 after purchasing an additional 93 shares during the period. RHL Group LLC bought a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $97,000. SLT Holdings LLC raised its stake in Eli Lilly and Company by 53.1% during the 4th quarter. SLT Holdings LLC now owns 421 shares of the company’s stock valued at $452,000 after purchasing an additional 146 shares during the period. Elite Life Management LLC raised its stake in Eli Lilly and Company by 92.5% during the 4th quarter. Elite Life Management LLC now owns 616 shares of the company’s stock valued at $652,000 after purchasing an additional 296 shares during the period. Finally, Genus Capital Management Inc. bought a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $4,944,000. Institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

  • Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
  • Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
  • Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
  • Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,066.59 on Monday. The company has a market cap of $1.00 trillion, a P/E ratio of 37.89, a P/E/G ratio of 1.16 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The business’s 50 day moving average price is $942.87 and its 200-day moving average price is $1,004.53. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts predict that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 24.58%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on LLY. Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,344.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 1st. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 6th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,220.37.

Check Out Our Latest Analysis on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.